Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553748 · ClinicalTrials.gov registry record · Phase 1
Phase I, Open Label, Single Center Safety Study of [F-18]FLT
A Phase 1 study of Brain Cancer, sponsored by Siemens Molecular Imaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT00553748 is a Phase 1 study of Brain Cancer that has completed, run by Siemens Molecular Imaging. The registered enrollment target is 11 participants, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00553748, a Phase 1 study of Brain Cancer, has completed, sponsored by Siemens Molecular Imaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a ten subject, phase 1 study. The purpose of the Phase 1 study is to demonstrate drug safety in a target group of subjects with high grade brain cancer. This population represents a potential clinical population that may benefit from this PET imaging tracer. The study will also begin collection of baseline imaging data and allow us to gain information to improve design and conduct of future trials.
Conditions Studied
Interventions
- DRUG F-18 FLT
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00553748
The ClinicalTrials.gov registry entry for NCT00553748 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Siemens Molecular Imaging, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Cancer appearing as the primary indexed condition, and to 1 intervention - of which F-18 FLT is the first listed.
NCT00553748 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00553748 about?
NCT00553748 is a clinical study titled "Phase I, Open Label, Single Center Safety Study of [F-18]FLT". This is a ten subject, phase 1 study. The purpose of the Phase 1 study is to demonstrate drug safety in a target group of subjects with high grade brain cancer. This population represents a potential clinical population that may benefit from this PET imaging tracer. The study will also begin collect...
What is the current status of trial NCT00553748?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-11. Estimated completion is 2008-05.
What conditions does trial NCT00553748 study?
This clinical trial studies the following conditions: Brain Cancer.
What interventions are being tested in trial NCT00553748?
The interventions under investigation include: F-18 FLT (DRUG).
Who is sponsoring clinical trial NCT00553748?
This trial is sponsored by Siemens Molecular Imaging, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00553748 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.